Skip to main content

Table 3 Survival rates (95% confidence intervals) of immunosuppressive/antiproliferative and vasoactive agents in 181 patients with Systemic sclerosis

From: Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort

ImmunosuppressivesMethotrexate *Cyclophosphamide **Mycophenolate***Azathioprine
 6 months0.91 (0.84–0.95)0.76 (0.60–0.86)0.95 (0.70–0.98)0.88 (0.62–0.97)
 12 months0.84 (0.75–0.90)0.59 (0.42–0.72)0.74 (0.48–0.88)0.78 (0.51–0.91)
 24 months0.75 (0.66–0.83)0.43 (0.27–0.58)0.63 (0.40–0.80)0.60 (0.34–0.78)
 36 months0.72 (0.62–0.80)0.26 (0.13–0.40)0.53 (0.32–0.74)0.47 (0.23–0.67)
 48 months0.65 (0.54–0.74)0.16 (0.06–0.30)0.40 (0.20–0.61)0.33 (0.12–0.54)
VasoactivesEndotelin-receptor antagonists+Sildenafil++Calcium channel blockers
 6 months0.92 (0.84–0.96)0.93 (0.69–0.99)0.99 (0.93–0.99)
 12 months0.88 (0.78–0.94)0.8 (0.52–0.93)0.97 (0.91–0.99)
 24 months0.86 (0.76–0.92)0.8 (0.52–0.93)0.91 (0.85–0.96)
 36 months0.84 (0.73–0.91)0.70 (0.41–0.88)0.87 (0.78–0.92)
 48 months0.79 (0.66–0.88)0.70 (0.41–0.88)0.83 (0.74–0.89)
  1. *0.001 vs. CYC, 0.039 vs. MMF, 0.001 vs. AZA
  2. **0.009 vs. MMF, 0.075 vs. AZA *** 0.337 vs. AZA
  3. + 0.256 vs. sildenafil, 0.562 vs. CCB ++ 0.187 vs. CCB
  4. Methotrexate and tocilizumab were administered for skin sclerosis or arthritis. Cyclophosphamide, mycophenolate, azathioprine, and rituximab were administered mainly for pulmonary fibrosis. Endothelin receptor antagonists (ERAs) and sildenafil were administered either for digital ulcers or pulmonary arterial hypertension and calcium channel blockers (CCB) were administered as first-line vasodilators